Reply to thread

J&J doesnt even LOOK at small companys' drugs worth less than $500M/yr revenue post launch, much less one thats FOUR YEARS in with negative returns.  YOU'RE DELUSIONAL. None of those companys need this dog, with its high oveorhead and minimum return.  Those companies you mention buy compounds from novel companies in Phase 1 or 2, and pre-launch phase 3.  They could get a better ROI investing elsewhere.


I really cannot believe that you all continue to drink the Kool-Aid!  Is that narcissist JE really THAT convincing of a liar, or are ya'll stupid?!